在高龄多病症住院患者中,IGF-I缺乏症患者的体腺功能
Olivia Tausendfreund1, Martin Bidlingmaier2, Sebastian Martini2
1Department of Medicine IV, University Hospital, LMU Munich, München, Germany. o.tausendfreund@med.uni-muenchen.de.
Pituitary
|May 31, 2024
概括
衰老的垂体腺保持其生长激素 (GH) 生产能力. 这表明,与年龄相关的体内热因轴衰减并不是由于脑下垂体GH分泌量减少.
科学领域:
- 内分泌学 在内分泌学.
- 老年学是指老年学的学科.
- 代谢过程中的代谢.
背景情况:
- 随着年龄的增长,人体热量轴的衰退是常见的.
- 原因是有争议的:降低垂体生长激素 (GH) 生产或外围GH抵抗.
- 在老年人中观察到胰岛素样生长因子I (IGF-I) 缺乏.
研究的目的:
- 为了调查与年龄相关的体质轴衰退的原因.
- 为了确定下垂体GH缺乏 (体质停止) 是否是IGF-I缺乏的老年患者的主要驱动因素.
- 通过GHRH/阿尔金因测试来评估垂体GH分泌能力.
主要方法:
- 研究了17名老年多病症患者 (平均年龄82岁),患有IGF-I缺乏症.
- 患者患有各种慢性和急性疾病.
- 进行了GHRH/阿尔金因刺激试验,以评估体轴.
主要成果:
- 在刺激后的平均峰值GH度为14.8μg/L.
- 在考虑性别和BMI的17名患者中,16名患者的垂体腺体得到了充分的刺激.
- 从GHRH/阿尔金因测试中没有报告任何显著的副作用.
结论:
- 随着年龄的增长,人体缩性垂体腺仍然保持其分泌能力.
- 年龄本身似乎并不是体轴功能衰退的主要原因.
- 这些发现表明,外围因素可能对与年龄相关的体内热因功能障碍有更大的贡献.
相关概念视频
Hypoglycemia and Glucagon
256
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
256
Insulin: Dosing Regimen and Adverse Effects
166
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
166
Major Hormones and Their Functions
375
Hormones, the biochemical messengers produced by endocrine glands, are pivotal in regulating bodily functions and maintaining homeostasis. Each hormone's balance is crucial; imbalances can lead to significant physiological disruptions. Major hormones include oxytocin, cortisol, epinephrine, estrogen, testosterone, thyroxine, growth hormone, insulin, and glucagon.
Oxytocin, produced in the hypothalamus and released by the pituitary gland, plays a role in social bonding, childbirth, and...
Oxytocin, produced in the hypothalamus and released by the pituitary gland, plays a role in social bonding, childbirth, and...
375
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.2K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.2K
Hormones of the Pituitary Gland
6.5K
The small, pea-sized pituitary gland is located at the base of the brain. It is crucial in regulating various bodily functions, from growth to reproduction. The gland is divided into the anterior lobe and the posterior lobe. The secretory cell clusters in the pars distalis of the anterior pituitary lobe are controlled by hypothalamic regulators and synthesize six primary hormones.
The most abundantly secreted hormone from the anterior lobe is the growth hormone, which controls overall growth by...
The most abundantly secreted hormone from the anterior lobe is the growth hormone, which controls overall growth by...
6.5K
Glucagon-like Receptor Agonists
316
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
316


